MedTrace Logo

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

NCT00514865 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2023-11-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder

Conditions

Interventions

DRUG

ONO-2333Ms Experimental 2

5-10 mg QD(once a day) for 8 weeks

DRUG

Placebo

0 mg QD(once a day) for 8 weeks

DRUG

ONO-2333Ms Experimental 1

1-2 mg QD(once a day) for 8 weeks

Sponsors & Collaborators

  • Ono Pharma USA Inc

    lead INDUSTRY

Principal Investigators

  • Katsutoshi Hatakeyama, M.S. · Ono Pharma USA Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-13
Primary Completion
2008-04-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514865 on ClinicalTrials.gov